====== Nelson Lee ======

{{ ::nlee_web.jpeg?200|}}

Dr. **Nelson Lee**, MD, MB.BS., MRCP(UK), FRCP(Lond), FRCP(Edin), FIDSA is a Chinese-Canadian [[infectious diseases]] researcher based in [[canada:alberta:Edmonton]], [[canada:Alberta]]. 

===== Education =====

Lee holds a Bachelor of Medicine and Bachelor of Surgery from the [[University of Hong Kong]].

He conducted research and completed his MD at the [[Chinese University of Hong Kong]]. He is a certified member of the [[Royal College of Physicians]] in the [[United Kingdom]]. He holds fellowships from the [[Royal College of Physicians of Edinburgh]], [[Royal College of Physicians of London]], [[Hong Kong College of Physicians]], [[Hong Kong Academy of Medicine]] and the [[Infectious Diseases Society of America]].

===== Career =====

Lee completed a clinical fellowship in HIV/AIDS research at [[St. Paul's Hospital]] through the [[University of British Columbia]] in 2001-2002.

==== Chinese University of Hong Kong ====

From 2014-2017, Lee completed an endowed professorship in infectious diseases at the [[Chinese University of Hong Kong]]. He served as Chair of the Scientific Committee of the 2016 [[OPTIONS for the Control of Influenza]] conference.
==== University of Alberta ====

Lee became a registered physician with the [[College of Physicians and Surgeons of Alberta]] in 2017.

Lee joined the faculty at the [[University of Alberta]]'s Department of Medicine in the Division of Infectious Diseases in 2018.((Soke, S. (2018, September 14). //Fresh faces || Nelson Lee.// University of Alberta. https://archive.ph/PrT5T)) He once again chaired the Scientific Committee of the [[OPTIONS for the Control of Influenza]] conference in 2019.

Lee has been a member of the [[European Society for Clinical Microbiology and Infectious Diseases]] (ESCMID)'s guidelines committee for influenza management since 2020.((//Lee, Nelson.// Dalla Lana School of Public Health. Retrieved October 26, 2022, from https://web.archive.org/web/20221026223237/https://www.dlsph.utoronto.ca/faculty-profile/lee-nelson/))

==== COVID-19 ====

During the [[COVID-19 pandemic]], Lee participated as an infectious disease specialist on the [[AHS COVID-19 Scientific Advisory Group]] under [[Alberta Health Services]]. He also served on the Serology Advisory Group and Antimicrobial Management Working Group for AHS in 2020 and 2021, and participated on a [[Health Canada]] Technical Advisory Committee on [[COVID-19]] and [[antivirals]].((//Lee, Nelson.// Dalla Lana School of Public Health. Retrieved October 26, 2022, from https://web.archive.org/web/20221026223237/https://www.dlsph.utoronto.ca/faculty-profile/lee-nelson/))

He departed the University of Alberta in July 2021 to begin a position as Professor and Interim Director of the new [[Institute for Pandemics]] at the [[University of Toronto]]'s [[Dalla Lana School of Public Health]].((//Nelson Lee.// LinkedIn. Retrieved October 26, 2022, from https://www.linkedin.com/in/nelson-lee-5732395a))
===== Research =====

Lee's research interests include [[emerging infectious diseases]], [[pandemics]], [[epidemics]], [[coronaviruses]], [[influenza viruses]], [[RSV]], [[pneumonia]], clinical [[epidemiology]], disease burden, health outcomes, transmission modes & prevention, [[antiviral]] & [[vaccine]] effectiveness, and [[clinical trials]].((//Lee, Nelson.// Dalla Lana School of Public Health. Retrieved October 26, 2022, from https://web.archive.org/web/20221026223237/https://www.dlsph.utoronto.ca/faculty-profile/lee-nelson/))

==== Funding ====

Lee has received various forms of funding from [[pharmaceutical_companies:Cidara Therapeutics]], [[pharmaceutical_companies:Genentech]], [[pharmaceutical_companies:Gilead Sciences]], [[pharmaceutical_companies:Janssen]], [[pharmaceutical_companies:Roche]], [[pharmaceutical_companies:Sanofi Pasteur]], [[pharmaceutical_companies:Seqirus]] and [[pharmaceutical_companies:Shionogi]].((Lee, N. (2018). //ICMJE Form for Disclosure of Potential Conflicts of Interest// (pp. 24–26). New England Journal of Medicine. https://web.archive.org/web/20220511231133/https://www.nejm.org/doi/suppl/10.1056/NEJMoa1716197/suppl_file/nejmoa1716197_disclosures.pdf)) ((Aziza, E., Slemko, J., Zapernick, L., Smith, S. W., Lee, N., & Sligl, W. I. (2021). //Outcomes among critically ill adults with influenza infection.// Official Journal of the Association of Medical Microbiology and Infectious Disease Canada, 6(4), 269–277. https://doi.org/10.3138/jammi-2021-0011))

He previously published research on [[SARS-CoV-1]] funded by the [[Research Fund for the Control of Infectious Diseases]].((Lee, N., Allen Chan, K. C., Hui, D. S., Ng, E. K. O., Wu, A., Chiu, R. W. K., Wong, V. W. S., Chan, P. K. S., Wong, K. T., Wong, E., Cockram, C. S., Tam, J. S., Sung, J. J. Y., & Lo, Y. M. D. (2004). //Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients.// Journal of Clinical Virology, 31(4), 304–309. https://doi.org/10.1016/j.jcv.2004.07.006))
===== Affiliations =====

Lee is a member of the board for the [[International Society of Influenza and other Respiratory Virus Diseases]] (ISIRV). He is a member of the College of Reviewers for the [[Canadian Institutes of Health Research]] (CIHR).((//College of Reviewers - Membership List.// (2022, October 19). Canadian Institutes of Health Research. https://cihr-irsc.gc.ca/e/51148.html)) He has also acted as a consultant for the [[World Health Organization]], and been on an expert panel for the [[Biomedical Advanced Research and Development Authority]] (BARDA) and the [[National Institutes of Health]] (NIH).